Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2008-05-06
2008-05-06
Haghighatian, Mina (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S046000, C424S434000, C424S489000, C514S826000, C514S851000
Reexamination Certificate
active
07368104
ABSTRACT:
A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
REFERENCES:
patent: 5612053 (1997-03-01), Baichwal et al.
patent: 6307060 (2001-10-01), Noe et al.
patent: 6406745 (2002-06-01), Talton
patent: 6613795 (2003-09-01), Noe et al.
patent: 6645466 (2003-11-01), Keller et al.
patent: 2003/0068280 (2003-04-01), Bannister et al.
patent: 2004/0028734 (2004-02-01), Bannister et al.
patent: WO 97/39758 (1997-10-01), None
patent: WO 98/34595 (1998-08-01), None
patent: WO 00/06121 (2000-02-01), None
patent: WO 00/07567 (2000-02-01), None
patent: WO 00/28979 (2000-05-01), None
Alex et al, American Journal of Critical Respiratory Care Medicine, 1999, 159(3); A823 (abstract/poster #A160).
Boyars, M.C. “COPD in the ambulatory elderly: Management update.”Geriatrics. Jun. 1988. 43(6): 29-32, 35-37, 40.
Cydulka, R.K. and C.L. Emerman. “Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease.”Ann. Emerg. Med. Apr. 1995 25(4): 470-473.
Disse, B., G.A. Speck, K.L. Rominger, T.J. Witek, Jr., and R. Hammer. “Tiotropium (Spiriva™): Mechanistical considerations and clinical profile in obstructive lung disease.”Life Sci. 1999. 64(6-7): 457-464.
Haddad, B., H. Patel, J.E. Keeling, M.H. Yacoub, P.J. Barnes, and M.G. Belvisi. “Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, In human and guinea-pig airways.”Br. J. Pharmacol. 1999. 127: 413-420.
Howder, C.L. “Antimuscarinic and βΓadrenoceptor bronchodilators in obstructive airways disease.”Respiratory Care. Dec. 1993. 38(12): 1364-1388.
Leckie, M.J., S.A. Bryan, T.T. Hansel, and P.J. Barnes. “Novel therapy for COPD.”Exp. Opin. Invest Drugs. 2000 9(1): 3-23.
Schroeckenstein, D.C., R.K. Bush, P. Chervinsky, W.W. Busse. “Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate.”J. Allergy Clin. Immunol. Jul. 1988. 82(1): 115-119.
Skorodin, M.S. “Pharmacotherapy for asthma and chronic obstructive pulmonary disease.”Arch Intern Med. Apr. 12, 1993. 153: 814-828.
Tzelepis, G., S. Komanapoili, D. Tyler, D. Vega, and A. Fulambarker. “Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease.”Eur. Respir. J. 1996. 9: 100-103.
Walker, IV, F.B., D.L. Kaiser, M.B. Kowal, and P.M. Suratt. “Prolonged effect of inhaled glycopyrrolate in asthma.”Chest. Jan. 1987. 91(1): 49-51.
Ziment, I. “Pharmacologic therapy of obstructive airway disease.”Clin. Chest Med. Sep. 1990. 11(3): 461-486.
Bannister Robin Mark
Gilbert Julian Clive
McGlashan Richards Andrew John
Morton David A. V.
Staniforth John
Haghighatian Mina
Saliwanchik Lloyd & Saliwanchik
Sosei R&D Ltd.
LandOfFree
Treatment of respiratory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of respiratory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of respiratory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2807487